Chromadex Corp (CDXC) 1.3350 $CDXC
Sports Nutrition Supplier BPI Sports Adopts ChromaDex® Quality Verification Seal Program
PR Newswire - Thu Feb 05, 5:25AM CST
ChromaDex Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that sports nutrition supplier BPI Sports has contracted with ChromaDex for third-party verification of BPI Sports' protein products.
ChromaDex® CEO to Present at The Sidoti & Company, LLC Emerging Growth Institutional Investor Forum on January 12th
PR Newswire - Tue Jan 06, 5:30AM CST
ChromaDex® Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at The Sidoti & Company, LLC's Emerging Growth Institutional Investor Forum on Monday, Jan. 12, 2015 at The Grand Hyatt Hotel in New York City.
NIH Publishes Results of Preclinical Collaboration with ChromaDex Showing Potential Benefit of Nicotinamide Riboside
PR Newswire - Wed Dec 10, 5:30AM CST
ChromaDex Corp. (OTCQX: CDXC), announced today that the results of a mouse study performed in collaboration with ChromaDex by the National Institute on Aging (NIA), a member of the National Institutes of Health (NIH), were published in Cell Metabolism in November 2014. The results indicated that nicotinamide riboside (NR) was effective at restoring NAD+ levels in mitochondria and rescuing phenotypes associated with a devastating accelerated aging disease known as Cockayne Syndrome (CS). The researchers concluded that NR showed promise as a potential therapy for the disease, as well as for other age-related neurodegenerative conditions. ChromaDex is an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries.
NeutriSci Commences Trading and Provides Corporate Update
Marketwired - Thu Dec 04, 1:12PM CST
NeutriSci International Inc. (the "Company" or "NeutriSci"
(TSX VENTURE: NU) is pleased to announce that it has commenced trading as a Tier 2 TSX-V issuer under the symbol NU.
NU.VN: 0.500 (+0.005)
ChromaDex announces USD750,000 cash from sale of its BluScience Line
M2 - Thu Dec 04, 5:30AM CST
Natural products company ChromaDex (Other OTC:CDXC) reported on Wednesday the receipt of approximately USD750,000 in cash in connection with the prior sale of its BluScience line to NeutriSci International.
ChromaDex® CEO to Present at The Benchmark Company, LLC's Micro Cap Discovery One-on-One Conference on Dec. 11
PR Newswire - Thu Dec 04, 5:30AM CST
ChromaDex® Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at The Benchmark Company, LLC's Micro Cap Discovery One-on-One Conference on Thursday, Dec. 11, 2014, located at the Palmer House Hilton in Chicago.
ChromaDex paid for NeutriSci shares
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 7:36AM CST
ChromaDex® Receives $750,000 Cash from Previous Sale of its BluScience(TM) Line
PR Newswire - Wed Dec 03, 5:30AM CST
ChromaDex® Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that it has received a cash payment of approximately $750,000 for the shares of NeutriSci International Inc. ("NeutriSci" , that the company received as part of its prior transaction with NeutriSci.
ChromaDex Licenses Exclusive Worldwide Patent Rights from the University of Mississippi for Microalgae Technology Targeting Immune Support
PR Newswire - Tue Dec 02, 7:00AM CST
ChromaDex Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has licensed exclusive worldwide rights from the University of Mississippi for several patents related to the isolation and use of immunostimulatory extracts from microalgae. The exclusive worldwide license covers U.S. Patent numbers 7,205,284 and 7,846,452.
ChromaDex wins two US patent for novel ingredient pterostilbene
M2 - Tue Nov 25, 6:23AM CST
Natural products company ChromaDex (OTCQX:CDXC) reported on Monday that it has received the US Patent and Trademark Office's patent 8,809,400 B2 ('400 patent) and 8,841,350 B2 ('350 patent) for the ingredient pterostilbene.
ChromaDex Announces Two Patent Issuances for Novel Ingredient, Pterostilbene
PR Newswire - Mon Nov 24, 7:25AM CST
The U.S. Patent and Trademark Office has granted patent #8,809,400 B2 (referred to as the '400 patent) and #8,841,350 B2 (referred to as the '350 patent) pertaining to the ingredient pterostilbene, both of which are licensed exclusively to ChromaDex Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. These are the second and third ChromaDex-held patents issued for pterostilbene and several additional patents are pending.
ChromaDex to begin human research on NIAGEN Nicotinamide Riboside in partnership with University of Birmingham and Wellcome Trust
M2 - Tue Nov 18, 6:40AM CST
Natural products company ChromaDex (OTCQX:CDXC) revealed on Monday the execution of a material transfer agreement (MTA) for its patented NIAGEN nicotinamide riboside for pre-clinical and human studies with the University of Birmingham.
University of Birmingham Receives Grant from Wellcome Trust to Support Human Research on ChromaDex's NIAGEN® Nicotinamide Riboside
PR Newswire - Mon Nov 17, 7:25AM CST
ChromaDex Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with the University of Birmingham, whereby it will provide quantities of its patented NIAGEN® nicotinamide riboside for pre-clinical and human studies.
Animal Study Confirms Results of ChromaDex Human Clinical Study on Weight Loss with Pterostilbene
PR Newswire - Wed Nov 12, 7:25AM CST
A recent study led by Saioa Gomez-Zorita published in the Journal of Agricultural and Food Chemistry has demonstrated the weight loss effects of pterostilbene in rats fed an obesogenic diet. The study confirms the results of a 2012 human clinical trial on the effect of pterostilbene on weight loss conducted by ChromaDex (OTCQX: CDXC), an innovative natural products company that manufactures a proprietary pterostilbene ingredient, pTeroPure®.
OTC Markets Group Welcomes ChromaDex to OTCQX®
PR Newswire - Mon Nov 10, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced ChromaDex Inc. (OTCQX: CDXC), an innovative natural products company, has qualified to trade on OTCQX®, the best marketplace.
ChromaDex to commence trading on OTCQX Marketplace on 10 November 2014
M2 - Mon Nov 10, 4:54AM CST
Natural products company ChromaDex (Other OTC:CDXC) said on Friday that its common stock will trade on OTCQX under the existing stock ticker 'CDXC' on 10 November 2014, following approval.
ChromaDex to Begin Trading on OTCQX Marketplace on November 10
PR Newswire - Fri Nov 07, 4:00PM CST
ChromaDex®Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today it has received approval for its common stock to trade on OTCQX®, the best marketplace for established global and growth companies. Trading on OTCQX will begin on Monday, November 10, 2014 under the Company's existing stock ticker "CDXC".
ChromaDex® Reports Ingredient Sales Grew 160% in the Third Quarter
PR Newswire - Thu Nov 06, 5:40AM CST
ChromaDex® Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today the financial results for the quarter ended September 27, 2014.
New Edition of the Hayes' Principles and Methods of Toxicology Provides Critical New Chapter on Food Safety and Foodborne Toxicants
PR Newswire - Mon Oct 06, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, has announced that two leaders of its Spherix Consulting affiliate, A. Wallace Hayes, Ph.D., senior science advisor, and Claire Kruger, Ph.D., president, served as editors for the sixth edition of the influential textbook, Hayes' Principles and Methods of Toxicology.
Sports Nutrition Supplier BPI Sports Adopts ChromaDex® Quality Verification Seal Program
PR Newswire - Thu Feb 05, 5:25AM CST
ChromaDex Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that sports nutrition supplier BPI Sports has contracted with ChromaDex for third-party verification of BPI Sports' protein products.
ChromaDex® CEO to Present at The Sidoti & Company, LLC Emerging Growth Institutional Investor Forum on January 12th
PR Newswire - Tue Jan 06, 5:30AM CST
ChromaDex® Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at The Sidoti & Company, LLC's Emerging Growth Institutional Investor Forum on Monday, Jan. 12, 2015 at The Grand Hyatt Hotel in New York City.
NIH Publishes Results of Preclinical Collaboration with ChromaDex Showing Potential Benefit of Nicotinamide Riboside
PR Newswire - Wed Dec 10, 5:30AM CST
ChromaDex Corp. (OTCQX: CDXC), announced today that the results of a mouse study performed in collaboration with ChromaDex by the National Institute on Aging (NIA), a member of the National Institutes of Health (NIH), were published in Cell Metabolism in November 2014. The results indicated that nicotinamide riboside (NR) was effective at restoring NAD+ levels in mitochondria and rescuing phenotypes associated with a devastating accelerated aging disease known as Cockayne Syndrome (CS). The researchers concluded that NR showed promise as a potential therapy for the disease, as well as for other age-related neurodegenerative conditions. ChromaDex is an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries.
NeutriSci Commences Trading and Provides Corporate Update
Marketwired - Thu Dec 04, 1:12PM CST
NeutriSci International Inc. (the "Company" or "NeutriSci"
(TSX VENTURE: NU) is pleased to announce that it has commenced trading as a Tier 2 TSX-V issuer under the symbol NU. NU.VN: 0.500 (+0.005)
ChromaDex announces USD750,000 cash from sale of its BluScience Line
M2 - Thu Dec 04, 5:30AM CST
Natural products company ChromaDex (Other OTC:CDXC) reported on Wednesday the receipt of approximately USD750,000 in cash in connection with the prior sale of its BluScience line to NeutriSci International.
ChromaDex® CEO to Present at The Benchmark Company, LLC's Micro Cap Discovery One-on-One Conference on Dec. 11
PR Newswire - Thu Dec 04, 5:30AM CST
ChromaDex® Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at The Benchmark Company, LLC's Micro Cap Discovery One-on-One Conference on Thursday, Dec. 11, 2014, located at the Palmer House Hilton in Chicago.
ChromaDex paid for NeutriSci shares
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 7:36AM CST
ChromaDex® Receives $750,000 Cash from Previous Sale of its BluScience(TM) Line
PR Newswire - Wed Dec 03, 5:30AM CST
ChromaDex® Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that it has received a cash payment of approximately $750,000 for the shares of NeutriSci International Inc. ("NeutriSci"
, that the company received as part of its prior transaction with NeutriSci. ChromaDex Licenses Exclusive Worldwide Patent Rights from the University of Mississippi for Microalgae Technology Targeting Immune Support
PR Newswire - Tue Dec 02, 7:00AM CST
ChromaDex Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has licensed exclusive worldwide rights from the University of Mississippi for several patents related to the isolation and use of immunostimulatory extracts from microalgae. The exclusive worldwide license covers U.S. Patent numbers 7,205,284 and 7,846,452.
ChromaDex wins two US patent for novel ingredient pterostilbene
M2 - Tue Nov 25, 6:23AM CST
Natural products company ChromaDex (OTCQX:CDXC) reported on Monday that it has received the US Patent and Trademark Office's patent 8,809,400 B2 ('400 patent) and 8,841,350 B2 ('350 patent) for the ingredient pterostilbene.
ChromaDex Announces Two Patent Issuances for Novel Ingredient, Pterostilbene
PR Newswire - Mon Nov 24, 7:25AM CST
The U.S. Patent and Trademark Office has granted patent #8,809,400 B2 (referred to as the '400 patent) and #8,841,350 B2 (referred to as the '350 patent) pertaining to the ingredient pterostilbene, both of which are licensed exclusively to ChromaDex Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. These are the second and third ChromaDex-held patents issued for pterostilbene and several additional patents are pending.
ChromaDex to begin human research on NIAGEN Nicotinamide Riboside in partnership with University of Birmingham and Wellcome Trust
M2 - Tue Nov 18, 6:40AM CST
Natural products company ChromaDex (OTCQX:CDXC) revealed on Monday the execution of a material transfer agreement (MTA) for its patented NIAGEN nicotinamide riboside for pre-clinical and human studies with the University of Birmingham.
University of Birmingham Receives Grant from Wellcome Trust to Support Human Research on ChromaDex's NIAGEN® Nicotinamide Riboside
PR Newswire - Mon Nov 17, 7:25AM CST
ChromaDex Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with the University of Birmingham, whereby it will provide quantities of its patented NIAGEN® nicotinamide riboside for pre-clinical and human studies.
Animal Study Confirms Results of ChromaDex Human Clinical Study on Weight Loss with Pterostilbene
PR Newswire - Wed Nov 12, 7:25AM CST
A recent study led by Saioa Gomez-Zorita published in the Journal of Agricultural and Food Chemistry has demonstrated the weight loss effects of pterostilbene in rats fed an obesogenic diet. The study confirms the results of a 2012 human clinical trial on the effect of pterostilbene on weight loss conducted by ChromaDex (OTCQX: CDXC), an innovative natural products company that manufactures a proprietary pterostilbene ingredient, pTeroPure®.
OTC Markets Group Welcomes ChromaDex to OTCQX®
PR Newswire - Mon Nov 10, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced ChromaDex Inc. (OTCQX: CDXC), an innovative natural products company, has qualified to trade on OTCQX®, the best marketplace.
ChromaDex to commence trading on OTCQX Marketplace on 10 November 2014
M2 - Mon Nov 10, 4:54AM CST
Natural products company ChromaDex (Other OTC:CDXC) said on Friday that its common stock will trade on OTCQX under the existing stock ticker 'CDXC' on 10 November 2014, following approval.
ChromaDex to Begin Trading on OTCQX Marketplace on November 10
PR Newswire - Fri Nov 07, 4:00PM CST
ChromaDex®Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today it has received approval for its common stock to trade on OTCQX®, the best marketplace for established global and growth companies. Trading on OTCQX will begin on Monday, November 10, 2014 under the Company's existing stock ticker "CDXC".
ChromaDex® Reports Ingredient Sales Grew 160% in the Third Quarter
PR Newswire - Thu Nov 06, 5:40AM CST
ChromaDex® Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today the financial results for the quarter ended September 27, 2014.
New Edition of the Hayes' Principles and Methods of Toxicology Provides Critical New Chapter on Food Safety and Foodborne Toxicants
PR Newswire - Mon Oct 06, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, has announced that two leaders of its Spherix Consulting affiliate, A. Wallace Hayes, Ph.D., senior science advisor, and Claire Kruger, Ph.D., president, served as editors for the sixth edition of the influential textbook, Hayes' Principles and Methods of Toxicology.
